• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Morphic Holding Inc. (Amendment)

    2/9/24 4:52:51 PM ET
    $MORF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MORF alert in real time by email
    SC 13G/A 1 d753706dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO 13d-2 (b)

    (Amendment No. 2)

     

     

    Morphic Holding, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    61775R105

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Partners VII, L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    1,860,498 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    1,860,498 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,860,498 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.7% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such are held of record by PP VII (as defined in Item 2(A) of the Original Schedule 13). PMC VII (as defined in Item 2(A) of the Original Schedule 13), the general partner of PP VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Quarterly Report on Form 10-Q, for the quarter ended September 30, 2023, as filed with the United States Securities and Exchange Commission on November 3, 2023 (the “Form 10-Q”).


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Entrepreneurs’ Fund VII, L.P.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

    SOLE VOTING POWER

     

    130,153 (1)

        6   

    SHARED VOTING POWER

     

    0

        7   

    SOLE DISPOSITIVE POWER

     

    130,153 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    0

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    130,153 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.3% (2)

    12   

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such are held of record by PEF VII (as defined in Item 2(A) of the Original Schedule 13). PMC VII, the general partner of PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q.


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    Polaris Management Co. VII, L.L.C.

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    1,990,651 (1)

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    1,990,651 (1)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,990,651 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.0% (2)

    12   

    TYPE OF REPORTING PERSON

     

    OO

    (1) 1,860,498 of such shares are held of record by PP VII and 130,153 of such shares are held of record by PEF VII. PMC VII, the general partner of each of PP VII and PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q.


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    David Barrett

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    145 (1)

        6   

    SHARED VOTING POWER

     

    1,990,651 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    145 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    1,990,651 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,990,796 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.0% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by David Barrett directly.

    (2)

    1,860,498 of such shares are held of record by PP VII and 130,153 of such shares are held of record by PEF VII. PMC VII, the general partner of each of PP VII and PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q.


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    Brian Chee

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    0

        6   

    SHARED VOTING POWER

     

    1,990,651 (1)

        7   

    SOLE DISPOSITIVE POWER

     

    0

        8   

    SHARED DISPOSITIVE POWER

     

    1,990,651 (1)

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,990,651 (1)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.0% (2)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    1,860,498 of such shares are held of record by PP VII and 130,153 of such shares are held of record by PEF VII. PMC VII, the general partner of each of PP VII and PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q.


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    Amir Nashat

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    39,605 (1)

        6   

    SHARED VOTING POWER

     

    1,990,651 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    39,605 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    1,990,651 (2)

     9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,030,256 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.1% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    (i) 145 of such shares are held by Amir Nashat directly, and (ii) 39,460 of such shares subject to stock option awards that have been granted to Amir Nashat in his capacity as a director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment (as defined in the Introductory Note below). Excludes 12,535 shares subject to stock option awards that have been granted to Amir Nashat in his capacity as a director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment.

    (2)

    1,860,498 of such shares are held of record by PP VII and 130,153 of such shares are held of record by PEF VII. PMC VII, the general partner of each of PP VII and PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 49,782,426 shares of the Issuer’s Common Stock, calculated as follows (i) 39,460 shares of the Issuer’s Common Stock subject to stock option awards that have been granted to Amir Nashat in his capacity as a director of the Issuer and that are exercisable as of or within 60 days of the filing of this Amendment plus (ii) 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q.


    CUSIP #61775R105

     

     1   

    NAME OF REPORTING PERSONS

     

    Bryce Youngren

     2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐  (b) ☒

     

     3   

    SEC USE ONLY

     

     4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    145 (1)

        6   

    SHARED VOTING POWER

     

    1,990,651 (2)

        7   

    SOLE DISPOSITIVE POWER

     

    145 (1)

        8   

    SHARED DISPOSITIVE POWER

     

    1,990,651 (2)

    9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,990,796 (1) (2)

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.0% (3)

    12   

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

    All of such shares are held by Bryce Youngren directly.

    (2)

    1,860,498 of such shares are held of record by PP VII and 130,153 of such shares are held of record by PEF VII. PMC VII, the general partner of each of PP VII and PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Based on 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q.


    SCHEDULE 13G

    CUSIP #61775R105

    Introductory Note.

    This Amendment No. 2 (this “Amendment No. 2”) amends and supplements the Schedule 13G originally filed by the Reporting Persons with the United States Securities and Exchange Commission (the “Commission”), as amended by Amendment No. 1 filed with the Commission on February 11, 2022 (collectively, the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 2 have the meanings ascribed to them in the Original Schedule 13G.

    ITEM 2(B). ADDRESS OF PRINCIPAL OFFICE

    The address for each of the Reporting Persons except for Chee is:

    c/o Polaris Partners

    One Marina Park Drive, 8th Floor

    Boston, MA 02210

    The address for Chee is:

    c/o Polaris Partners

    1 Letterman Drive

    Building C, Suite 3600

    San Francisco, CA 94129

    ITEM 4. OWNERSHIP 

    The approximate percentages of Common Stock reported as beneficially owned by the Reporting Persons are based upon 49,742,966 shares of the Issuer’s Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q filed with the Commission on November 3, 2023.

    The following information with respect to the ownership of the common stock of the Issuer by the Reporting Persons filing this Statement is provided as of December 31, 2023:

    (a) Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

    (b) Percent of Class:

    See Row 11 of cover page for each Reporting Person.

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.


    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    *

    Except to the extent of their pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    ITEM

    5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    ☒


    CUSIP #61775R105

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 9, 2024

     

    POLARIS PARTNERS VII, L.P.
    By:   Polaris Management Co. VII, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS ENTREPRENEURS’ FUND VII, L.P.
    By:   Polaris Management Co. VII, L.L.C.
    By:   *
      Authorized Signatory
    POLARIS MANAGEMENT CO. VII, L.L.C.
    By:   *
      Authorized Signatory
    BRYCE YOUNGREN
    By:   *
      Bryce Youngren
    DAVID BARRETT
    By:   *
      David Barrett
    BRIAN CHEE
    By:   *
      Brian Chee
    AMIR NASHAT
    By:   *
      Amir Nashat
    *By:   /s/ Lauren Crockett
    Name:   Lauren Crockett
      Attorney-in-Fact

    [*This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $MORF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MORF

    DatePrice TargetRatingAnalyst
    12/8/2023$46.00Buy
    Citigroup
    9/25/2023$61.00 → $33.00Hold
    Stifel
    9/25/2023Buy → Neutral
    BTIG Research
    8/9/2023$69.00 → $61.00Buy → Hold
    Stifel
    9/7/2022$44.00Buy
    Stifel
    7/20/2022$45.00Outperform
    SVB Leerink
    3/31/2022$68.00Buy
    Canaccord Genuity
    2/25/2022$82.00 → $76.00Outperform
    RBC Capital
    More analyst ratings

    $MORF
    SEC Filings

    See more
    • SEC Form 15-12G filed by Morphic Holding Inc.

      15-12G - Morphic Holding, Inc. (0001679363) (Filer)

      8/26/24 7:39:57 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:27:56 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:25:26 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/21/24 4:36:17 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:12:13 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nashat Amir closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:11:28 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/15/23 7:00:10 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/14/23 7:04:11 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Morphic with a new price target

      Citigroup initiated coverage of Morphic with a rating of Buy and set a new price target of $46.00

      12/8/23 7:51:26 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Morphic with a new price target

      Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously

      9/25/23 11:48:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic downgraded by BTIG Research

      BTIG Research downgraded Morphic from Buy to Neutral

      9/25/23 7:17:39 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

      Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Morphic Holding, Inc. (NASDAQ:MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcera

      7/8/24 6:45:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/12/24 9:40:06 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/7/24 7:47:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      7/8/24 10:07:20 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Leadership Updates

    Live Leadership Updates

    See more
    • Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

      WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. "Simon brings clinical development expe

      3/19/24 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

      -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022. 2022 and Recent Corporate H

      2/23/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

      WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs. Ms. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences. "Joanne arrives at Morphic at a promising time. We are advancing clinical and pre-clinical integrin inhibitors generated by the MInT Platform and Joanne brings successful leadership experience across the full spectrum of regulatory affairs from preclinical activities through drug commer

      5/18/22 7:30:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

      -Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre

      11/3/23 7:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

      WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via

      10/9/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care